mRNA-Based Vaccine Development
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "DNA and mRNA Vaccines".
Deadline for manuscript submissions: closed (31 July 2024) | Viewed by 10923
Special Issue Editors
Interests: mRNA vaccines; innovations; next generation vaccines; infectious diseases
Special Issue Information
Dear Colleagues,
The COVID-19 pandemic has had a devastating impact worldwide, causing widespread illness, loss of life, and economic hardship. However, the rapid development of mRNA technology platforms has offered a glimmer of hope in the fight against the pandemic. Two of the most widely administered vaccines against SARS-CoV-2 are based on mRNA technology, highlighting the potential of this innovative approach for preventing and controlling future epidemics and pandemics. While mRNA-based vaccines have shown promising results, there are still significant challenges including, e.g., the sub-optimal expression of antigens invivo, stability at ultra cold temperatures, higher cost of goods, etc.
Advancements in the existing mRNA technology and the fostering of innovative approaches are key to facilitating the discovery and development of improved vaccines. The scope of this topic will include original artciles related to improving mRNA replicons/constructs, finding ways to improve immunogenicity and reduce reactogenicity, investigating targeted delivery, formulation strategies, exploring alternative routes of administration, reducing vaccine development timelines and more.
Dr. Arun Kumar
Dr. Martina Ochs
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- mRNA vaccines
- mRNA delivery
- infectious diseases
- mRNA innovations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
